A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced p...
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
About this item
Full title
Author / Creator
Pal, Sumanta K , Tangen, Catherine , Thompson, Ian M , Balzer-Haas, Naomi , George, Daniel J , Heng, Daniel Y C , Shuch, Brian , Stein, Mark , Tretiakova, Maria , Humphrey, Peter , Adeniran, Adebowale , Narayan, Vivek , Bjarnason, Georg A , Vaishampayan, Ulka , Alva, Ajjai , Zhang, Tian , Cole, Scott , Plets, Melissa , Wright, John and Lara, Primo N
Publisher
England: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
England: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
MET (also known as hepatocyte growth factor receptor) signalling is a key driver of papillary renal cell carcinoma (PRCC). Given that no optimal therapy for metastatic PRCC exists, we aimed to compare an existing standard of care, sunitinib, with the MET kinase inhibitors cabozantinib, crizotinib, and savolitinib for treatment of patients with PRCC...
Alternative Titles
Full title
A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial
Authors, Artists and Contributors
Author / Creator
Tangen, Catherine
Thompson, Ian M
Balzer-Haas, Naomi
George, Daniel J
Heng, Daniel Y C
Shuch, Brian
Stein, Mark
Tretiakova, Maria
Humphrey, Peter
Adeniran, Adebowale
Narayan, Vivek
Bjarnason, Georg A
Vaishampayan, Ulka
Alva, Ajjai
Zhang, Tian
Cole, Scott
Plets, Melissa
Wright, John
Lara, Primo N
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8687736
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8687736
Other Identifiers
ISSN
0140-6736,1474-547X
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(21)00152-5
